| Ticker: SIBI | 505 Coast Boulevard South, Suite 300 | |
| Exchange: NASDAQ-National Market | La Jolla, California 92037 | |
| Industry: Manufacturing | (619) 452-5892 |
| Type of Shares: | Common Shares | Filing Date: | 3/21/96 | |
| U.S. Shares: | 2,100,000 | Offer Date: | 5/9/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,100,000 | Offer Price: | $11.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.77 | |
| Offering Amount: | $25,200,000 | Selling: | $0.46 | |
| Expenses: | $580,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,873,138 |
| Manager | Tier | Phone |
| Salomon Brothers Inc. | Lead Manager | (212) 783-2947 |
| Needham & Company | Co-manager | (212) 371-8300 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Auditor: Price Waterhouse | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $10.45 | Assets: | $18.25 | ||
| Net Income: | $2.93 | Liabilities: | $3.14 | ||
| EPS: | $0.41 | Equity: | $15.11 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company researches and develops novel drugs for the treatment of central nervous system disorders, including Parkinson's disease, Alzheimer's disease, stroke, schizophrenia and epilepsy. The Company is engaged in the discovery and development of novel, small molecule therapeutics for disorders of the central nervous system based on the Company's unique approach to characterizing the molecular process involved in such disorders. The Company's technology permits the targeted identification of compounds that are selective for specific receptor/ion channel subtypes. The Company's strategy is to utilize its technologies to discover and develop proprietary CNS drug candidates and collaborate with corporate partners for the advanced development and commercialization of such candidates. SIBIA has established a leading proprietary position in human receptor/ion channel subtype technology. The Company has made significant scientific and technological advances by cloning key human neuronal receptor/ion channels, expressing them in stable cell lines and developing the resulting recombinant cell lines into functional assays for drug screening. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development activities, working capital and general corporate purposes, which may include capital expenditures and acquisitions. |
©1996 IPO Data Systems, Inc. - All rights reserved.